培土生金法治疗晚期非小细胞肺癌证型变化的研究
|
摘要
目的
研究在“培土生金”法指导下组成的科室肺癌协定1号方治疗ⅢB／Ⅳ期非小细胞肺癌患者证型的变化,并揭示证型变化的实质,为临床辨证论治及优化治疗方案提供一定依据。
方法
本研究采用前瞻性的研究方法。研究对象为2009年3月至2010年3月期间广东省中医院门诊及住院部病人,将符合入选条件的60例患者辨证给予我科肺癌协定1号方,采用病例观察表,观察治疗前及治疗后病人的证型变化,观察期为2月。全部数据结果采用SPSS 13.0统计软件进行分析,计量资料采用t检验,计数资料采用卡方检验,等级资料采用秩和检验等方法进行分析,以P＜0.05为有显著性差异。
结果
1.通过对主要症候因子的分析,经过卡方检验,治疗前后P＜0.05,有显著性差异的证候主要有倦怠乏力,呼吸气短,口干、干咳少痰、自汗盗汗、咳嗽咯白痰。
2.分析单一证型(气虚证、阴虚证、血瘀证、痰湿证、热毒证)共138例次(因观察病例采取单证,故中医证型相加之和超过60例),治疗前按证候发生率排列由多至少为气虚证48例(80%)>阴虚证30例(50%)>痰湿证28例(46.7%)>血瘀证24例(40%)>热毒证8例(13.3%)；治疗后按证候发生率排列由多至少为气虚证35例(58.3%)>血瘀证30例(50%)>痰湿证23例(38.3%)>阴虚证19例(31.7%)>热毒证6例(10%)。
3.ⅢB／Ⅳ期非小细胞肺癌患者在舌象方面的研究：舌色分淡红、红、淡暗、暗红、淡白5种,治疗前按比例多少排列：暗红舌(38.3%)>淡暗舌(30%)>红舌(13.3%)>淡白舌(11.7%)>淡红舌(6.7%)；治疗后按比例多少排列淡暗舌(41.7%)>暗红舌(21.7%)>淡白舌(13.3%)>淡红舌(11.7%)=红舌(11.7%),比较治疗前后舌色的变化,P＜0.05,前后舌色具有显著性差异。舌苔治疗前按比例多少排列：白腻苔(55%)>薄黄苔(25%)>薄白苔(11.7%)>剥少(6.7%)>黄腻苔(1.7%)；治疗后按比例多少排列：白腻苔(45%)>薄白苔(31.7%)>薄黄苔(11.7%)>剥少(10%)>黄腻苔(1.7%),比较舌苔治疗前后变化,P＜0.05,前后舌苔有居显著性差异。
4.在面色方面,治疗前面色比例由多至少排列为白(68.3%)>黑(20%)>红(8.3%)>黄(3.3%)；治疗后面色比例由多至少排列为白(53.3%)>黑(25%)>红(11.7%)>黄(10%),治疗前后面色比较,P<0.05,治疗前后面色有显著性差异。
5.在脉象方面,治疗前按比例多少排列：细脉(45%)>沉脉(13%)>滑脉(16.7%)>数脉(10%)>弦脉(6.7%)；治疗后按比例多少排列细脉(31.7%)>滑脉(26.7%)>沉脉(20%)>数脉(11.7%)>弦脉(10%)。P>0.05,治疗前后对比无明显差异。
结论
1.肺癌1号方治疗晚期非小细胞肺癌患者,治疗前后舌质、舌苔、面色均有明显变化,症状明显改善的有倦怠乏力、呼吸气短、口干舌燥、干咳少痰、潮热盗汗、咳嗽咯白痰；证型方面,总的来说虚证(气虚证、阴虚证)较实证(痰湿证、血瘀证、热毒证)为多；治疗前后变化明显的为气虚证、阴虚证,治疗前后无明显变化的为痰湿证、血瘀证、热毒证。
2.“培土生金”法指导下组成的肺癌1号方治疗晚期非小细胞肺癌患者能明显改善气虚证及阴虚证,揭示了晚期非小细胞肺癌患者气虚证及阴虚证的本质正是由于脾胃功能虚弱,而变生诸症,提示在临床上顾护脾胃的重要性。该法对于实证(痰湿证、血瘀证、热毒证)的改善未能显示出明显的效果,有待进一步的研究,建议可在此方的基础上,适当增加驱邪药物。
Objectives
To analyze the syndrome changes for the patients of the stage IIIB/IV non-small lung cancer who received the therapy of NO.1 Prescription of lung cancer which was composed by the rule "Strengthen earth to generate metal" Provided evidence for the different clinical treatment and optimization treatment.
Methods
The forward-looking methods was used in the study, from March 2009 to March 2010 period,60 patients who was confirmed diagnosis of stage III/IV NSCLC were enrolled. The patients received NO.1 Prescription of lung cancer by different treatment. The changes of syndrome were observated in two months with Case observation table. All data results were analyzed by SPSS 13.0 statistical software. Measurement data using t test, chi-square test with count data, grade data methods such as Wilcoxon test was used to analyze, by P< 0.05 with Significance mean.
Result
1.The symptom was analyzed by Chi-square test, significant differences of syndrome before and after the treatment were Lassitude, shortness of breath, dry mouth, dry cough with scanty sputum, spontaneous sweating, coughing slightly white sputum.
2.138 single syndromes (Qi deficiency, Yin deficiency, blood stasis, phlegm, fever and toxic syndrome) were analyzed, The single syndrome was used for the observation, so the sum of syndromes was more than 60 cases. Before the treatment, before the treatment, the incidence of the syndrome was arranged with at least by the more:Qi Deficiency 48 cases (80%)> Yin deficiency 30 cases (50%)> phlegm in 28 cases (46.7%)> blood stasis in 24 patients (40%)> heat-toxin syndrome in 8 cases (13.3%); after the treatment, the incidence of the syndrome was arranged with at least by the more:qi deficiency (58.3%)> blood stasis of 30 patients (50%)> 23 cases of phlegm (38.3%)> Yin deficiency in 19 cases (31.7%)> Heat toxic syndrome in 6 cases (10%).
3. The tongue color of 60 patients of stageⅢB/Ⅳnon-small cell lung cancer were classified into 5 Category:Pink, red, light dark, dark red, pale. before the treatment, the incidence of the syndrome was arranged with at least by the more:dark red tongue (38.3%)> short dark tongue (30%)> red tongue (13.3%)> pale tongue (11.7%)> pink tongue (6.7%); after the treatment, the incidence of the syndrome was arranged with at least by the more:light dark tongue (41.7%)> dark red tongue (21.7%)> pale tongue (13.3%)> pink tongue (11.7%) = Red tongue (11.7%) compared the change of tongue color before and after treatment, P<0.05, The changes was a significant with different color. Coating on the tongue was observed, before the treatment, the incidence of the syndrome was arranged with at least by the more:greasy moss (55%)> thin yellow fur (25%)> thin white coating (11.7%)> stripping less (6.7%)> yellow sticky coating (1.7%); after the treatment, the incidence of the syndrome was arranged with at least by the more:greasy coating (45%)> thin white coating (31.7%)> thin yellow fur (11.7%)> stripping less (10%)> yellow sticky coating (1.7%) compared changes in tongue before and after treatment, P< 0.05, before and after the tongue has a significant difference.
4.In the complexion, before the treatment, the incidence of the syndrome was arranged with at least by the more:white (68.3%)> Black (20%)> red (8.3%)> yellow (3.3%); after the treatment, the incidence of the syndrome was arranged with at least by the more:white (53.3%)> Black (25%)> Red (11.7%)> yellow (10%), looking before and after treatment compared, P<0.05, before and after treatment were significantly different complexion.
5. In the pulse, before the treatment, the incidence of the syndrome was arranged with at least by the more:small veins (45%)> Journal of veins (13%)> slippery pulse (16.7%)> the number of veins (10%)> String pulse (6.7%); after the treatment, the incidence of the syndrome was arranged with at least by the more:small veins (31.7%)> slippery pulse (26.7%)> Journal of veins (20%)> the number of contacts (11.7%)> String pulse (10%). P>0.05, no significant difference was showed before and after treatment.
Conclusion
1.The tongue color, Coating on the tongue, complexion of the patients were changed significantly with statistical significance before and after the treatment, The symptoms improved significantly were fatigue, shortness of breath, dry mouth, dry cough with less sputum, fever and night sweating, cough, phlegm white slightly;On the respect of syndrome, In general, the deficiency syndrome(qi deficiency, yin deficiency) was more than the positive syndrome(phlegm, blood stasis and heat toxin card), the changes before and after treatment are qi deficiency, yin deficiency, qi deficiency which improved significantly; the changes before and after treatment are phlegm, blood stasis and heat toxin syndrome which was Pointless.
2. The NO.1 Prescription of lung cancer was composed by the rule "Strengthen earth to generate metal", the result showed that Qi deficiency and Yin deficiency was improved significantly by the The NO.1 Prescription of lung cancer, No enough effect was showed in the the evidence (blood stasis, phlegm, fever and toxic syndrome). Exorcism drugs was suggested on the further study.
研究在“培土生金”法指导下组成的科室肺癌协定1号方治疗ⅢB／Ⅳ期非小细胞肺癌患者证型的变化,并揭示证型变化的实质,为临床辨证论治及优化治疗方案提供一定依据。
方法
本研究采用前瞻性的研究方法。研究对象为2009年3月至2010年3月期间广东省中医院门诊及住院部病人,将符合入选条件的60例患者辨证给予我科肺癌协定1号方,采用病例观察表,观察治疗前及治疗后病人的证型变化,观察期为2月。全部数据结果采用SPSS 13.0统计软件进行分析,计量资料采用t检验,计数资料采用卡方检验,等级资料采用秩和检验等方法进行分析,以P＜0.05为有显著性差异。
结果
1.通过对主要症候因子的分析,经过卡方检验,治疗前后P＜0.05,有显著性差异的证候主要有倦怠乏力,呼吸气短,口干、干咳少痰、自汗盗汗、咳嗽咯白痰。
2.分析单一证型(气虚证、阴虚证、血瘀证、痰湿证、热毒证)共138例次(因观察病例采取单证,故中医证型相加之和超过60例),治疗前按证候发生率排列由多至少为气虚证48例(80%)>阴虚证30例(50%)>痰湿证28例(46.7%)>血瘀证24例(40%)>热毒证8例(13.3%)；治疗后按证候发生率排列由多至少为气虚证35例(58.3%)>血瘀证30例(50%)>痰湿证23例(38.3%)>阴虚证19例(31.7%)>热毒证6例(10%)。
3.ⅢB／Ⅳ期非小细胞肺癌患者在舌象方面的研究：舌色分淡红、红、淡暗、暗红、淡白5种,治疗前按比例多少排列：暗红舌(38.3%)>淡暗舌(30%)>红舌(13.3%)>淡白舌(11.7%)>淡红舌(6.7%)；治疗后按比例多少排列淡暗舌(41.7%)>暗红舌(21.7%)>淡白舌(13.3%)>淡红舌(11.7%)=红舌(11.7%),比较治疗前后舌色的变化,P＜0.05,前后舌色具有显著性差异。舌苔治疗前按比例多少排列：白腻苔(55%)>薄黄苔(25%)>薄白苔(11.7%)>剥少(6.7%)>黄腻苔(1.7%)；治疗后按比例多少排列：白腻苔(45%)>薄白苔(31.7%)>薄黄苔(11.7%)>剥少(10%)>黄腻苔(1.7%),比较舌苔治疗前后变化,P＜0.05,前后舌苔有居显著性差异。
4.在面色方面,治疗前面色比例由多至少排列为白(68.3%)>黑(20%)>红(8.3%)>黄(3.3%)；治疗后面色比例由多至少排列为白(53.3%)>黑(25%)>红(11.7%)>黄(10%),治疗前后面色比较,P<0.05,治疗前后面色有显著性差异。
5.在脉象方面,治疗前按比例多少排列：细脉(45%)>沉脉(13%)>滑脉(16.7%)>数脉(10%)>弦脉(6.7%)；治疗后按比例多少排列细脉(31.7%)>滑脉(26.7%)>沉脉(20%)>数脉(11.7%)>弦脉(10%)。P>0.05,治疗前后对比无明显差异。
结论
1.肺癌1号方治疗晚期非小细胞肺癌患者,治疗前后舌质、舌苔、面色均有明显变化,症状明显改善的有倦怠乏力、呼吸气短、口干舌燥、干咳少痰、潮热盗汗、咳嗽咯白痰；证型方面,总的来说虚证(气虚证、阴虚证)较实证(痰湿证、血瘀证、热毒证)为多；治疗前后变化明显的为气虚证、阴虚证,治疗前后无明显变化的为痰湿证、血瘀证、热毒证。
2.“培土生金”法指导下组成的肺癌1号方治疗晚期非小细胞肺癌患者能明显改善气虚证及阴虚证,揭示了晚期非小细胞肺癌患者气虚证及阴虚证的本质正是由于脾胃功能虚弱,而变生诸症,提示在临床上顾护脾胃的重要性。该法对于实证(痰湿证、血瘀证、热毒证)的改善未能显示出明显的效果,有待进一步的研究,建议可在此方的基础上,适当增加驱邪药物。
Objectives
To analyze the syndrome changes for the patients of the stage IIIB/IV non-small lung cancer who received the therapy of NO.1 Prescription of lung cancer which was composed by the rule "Strengthen earth to generate metal" Provided evidence for the different clinical treatment and optimization treatment.
Methods
The forward-looking methods was used in the study, from March 2009 to March 2010 period,60 patients who was confirmed diagnosis of stage III/IV NSCLC were enrolled. The patients received NO.1 Prescription of lung cancer by different treatment. The changes of syndrome were observated in two months with Case observation table. All data results were analyzed by SPSS 13.0 statistical software. Measurement data using t test, chi-square test with count data, grade data methods such as Wilcoxon test was used to analyze, by P< 0.05 with Significance mean.
Result
1.The symptom was analyzed by Chi-square test, significant differences of syndrome before and after the treatment were Lassitude, shortness of breath, dry mouth, dry cough with scanty sputum, spontaneous sweating, coughing slightly white sputum.
2.138 single syndromes (Qi deficiency, Yin deficiency, blood stasis, phlegm, fever and toxic syndrome) were analyzed, The single syndrome was used for the observation, so the sum of syndromes was more than 60 cases. Before the treatment, before the treatment, the incidence of the syndrome was arranged with at least by the more:Qi Deficiency 48 cases (80%)> Yin deficiency 30 cases (50%)> phlegm in 28 cases (46.7%)> blood stasis in 24 patients (40%)> heat-toxin syndrome in 8 cases (13.3%); after the treatment, the incidence of the syndrome was arranged with at least by the more:qi deficiency (58.3%)> blood stasis of 30 patients (50%)> 23 cases of phlegm (38.3%)> Yin deficiency in 19 cases (31.7%)> Heat toxic syndrome in 6 cases (10%).
3. The tongue color of 60 patients of stageⅢB/Ⅳnon-small cell lung cancer were classified into 5 Category:Pink, red, light dark, dark red, pale. before the treatment, the incidence of the syndrome was arranged with at least by the more:dark red tongue (38.3%)> short dark tongue (30%)> red tongue (13.3%)> pale tongue (11.7%)> pink tongue (6.7%); after the treatment, the incidence of the syndrome was arranged with at least by the more:light dark tongue (41.7%)> dark red tongue (21.7%)> pale tongue (13.3%)> pink tongue (11.7%) = Red tongue (11.7%) compared the change of tongue color before and after treatment, P<0.05, The changes was a significant with different color. Coating on the tongue was observed, before the treatment, the incidence of the syndrome was arranged with at least by the more:greasy moss (55%)> thin yellow fur (25%)> thin white coating (11.7%)> stripping less (6.7%)> yellow sticky coating (1.7%); after the treatment, the incidence of the syndrome was arranged with at least by the more:greasy coating (45%)> thin white coating (31.7%)> thin yellow fur (11.7%)> stripping less (10%)> yellow sticky coating (1.7%) compared changes in tongue before and after treatment, P< 0.05, before and after the tongue has a significant difference.
4.In the complexion, before the treatment, the incidence of the syndrome was arranged with at least by the more:white (68.3%)> Black (20%)> red (8.3%)> yellow (3.3%); after the treatment, the incidence of the syndrome was arranged with at least by the more:white (53.3%)> Black (25%)> Red (11.7%)> yellow (10%), looking before and after treatment compared, P<0.05, before and after treatment were significantly different complexion.
5. In the pulse, before the treatment, the incidence of the syndrome was arranged with at least by the more:small veins (45%)> Journal of veins (13%)> slippery pulse (16.7%)> the number of veins (10%)> String pulse (6.7%); after the treatment, the incidence of the syndrome was arranged with at least by the more:small veins (31.7%)> slippery pulse (26.7%)> Journal of veins (20%)> the number of contacts (11.7%)> String pulse (10%). P>0.05, no significant difference was showed before and after treatment.
Conclusion
1.The tongue color, Coating on the tongue, complexion of the patients were changed significantly with statistical significance before and after the treatment, The symptoms improved significantly were fatigue, shortness of breath, dry mouth, dry cough with less sputum, fever and night sweating, cough, phlegm white slightly;On the respect of syndrome, In general, the deficiency syndrome(qi deficiency, yin deficiency) was more than the positive syndrome(phlegm, blood stasis and heat toxin card), the changes before and after treatment are qi deficiency, yin deficiency, qi deficiency which improved significantly; the changes before and after treatment are phlegm, blood stasis and heat toxin syndrome which was Pointless.
2. The NO.1 Prescription of lung cancer was composed by the rule "Strengthen earth to generate metal", the result showed that Qi deficiency and Yin deficiency was improved significantly by the The NO.1 Prescription of lung cancer, No enough effect was showed in the the evidence (blood stasis, phlegm, fever and toxic syndrome). Exorcism drugs was suggested on the further study.
引文
[1]Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinationa, phaseⅢstudy of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the TAX 326study group [J]. J Clin Oncol,2003; 21(16):3016-3024.
[2]Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Ensl J Med,2002; 346(2): 92-98.
[3]Kubota K,Watanabe K,Kunitoh H,et al.Phase Ⅲ randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stag e Ⅳ non-small-cell lung cancer:the Japanese Taxotere Lung Cancer Study Group [J]. J Clin Oncol,2004; 22 (2):254-261.
[4]ParkinDM, BrayFB, PisaniP. Global cancer statistics[J]. CA Cancer J Clin, 2005,55(2):74—108.
[5]支修益.我国肺癌流行病学的研究[J]中国处方药,2009；2(83)：56—57。
[6]Jovanovic D, Popevic S, StevicR, etal. Changes in lung cancer presentation in 13year interval (comparison of data bases from 1990 and 2003)[J]. Lung Cancer,2005,49(Suppl2):191.
[7]YangP, WilliamsB, AdjeiA, etal. Characteristics of lung cancer patients who were diagnosed younger than 50 or older than 80 years of age. LungCancer, 2005,49(Suppl2):S22-58.
[8]王瑾,许峰,周清华.肺癌流行病学研究进展[J]中国肺癌杂志,2005：8(5)：395—398.
[9]AllenJ, JahanzebM. Neoadjuvant chemotherapy in stage III NSCLC[J].J Natl Compr Cane Netw,2008; 6(3):285-293.
[10]谷力加,吴一龙,冯卫能.237例肺癌外科治疗影响预后因素的分析[J].中国肿瘤临床,2002；29(6)：410-412.
[11]Baumann M A pold S, Petemon C, et al. Dose and fraction—ation concepts in the primary radiotherapy of non—small cell lung cancer [J]. Lung Cancer.2001,33:S43—S45
[12]徐建宇.非小细胞肺癌非常规分割三维适形放射治疗的研究现状.实用肿瘤内科学.2008：22(5)：34-35.
[13]OnishiH, ArakiT, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma:clinical outcomes in 245 Subjects in a Japanese multi institutional study. Cancer 2004; 101 (7):1623-1631.
[14]0nishiH, ShiratoH, NagataY, et al.Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ non-small cell lung cancer:updated results of 257 patients in a Japanese multi-institutional study[J]. Thorac Oncol 2007;2(7Suppl 3):S94-100.
[15]Chemotherapy in non small cell lung cancer a meta-analysis using updated data on individual patients from 52 randomised clinical trials[J]. BMJ, 1995; 311:899—909.
[16]Pignon JP, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Grou[J]p. Clin Oncol 2008;26(21):3552-3559.
[17]Scagliotti GV, De Marlnis F, Rinaldi M, et al. Phase Ⅰ11 Randomized trial comparing three platinum-based doublets in advanced non—small cell lung cancer [J]. Clin Oncol,2002,20(21):4285—4291.
[18]Hainsworth JD, Gray JR, Morrlssey LH, et al. Long—term follow—up of patients treated with pa elitaxel/earbo platin—based chemotherapy for advanced non-small-cell lung cancer:sequential phase Ⅱ trials of the minnie pearl cancer research network [J]. ClinOncol,2002,20(13):2937-2942.
[19]Laack E, Mende T, Drk H, et al. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer:a phase Ⅱ trial[J]. Eur J Cancer,2002,38(5):654-660.
[20]Fossella FV, DeVoreKerr RN, etal. Randomized phase Ⅲ trial of ocetaxel versus vinorel bineo rifosf amidein patient swith advanced on-small—cell lung cancer previous lytreated with platinum—containing chemotherapy regime. TheTAX320 Non—Small Cell Lung Cancer Study Group. JClinOncol,2000, 18(12):2354--2362.
[21]Fossella. FV, LynchT'Shepherd.FA. Second-line chemotherapy For NSCLC: establishing a gold standard[J]. Lung Cancer.2002; 38 (14):5—12.
[22]Demarinis F, PaulS, Hanna N, etal. Survival update for the phaseⅢstudy of pemetre xedvsdocetaxel in non-small cell lung cancer(NSCLC) [J]. ASCO Meeting Abstracts, Jun2006; 24:7133.
[23]熊慧华,邹艳梅,夏署.吉非替尼与多西紫杉醇二线治疗非小细胞肺癌的疗效比较[J].临床内科杂志,2008；25(8)：537-538.
[24]Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small--cell lung cancer after failure of at least one prior chemotherapy regimen[J]. Clin Cancer Res,2005,11(18):6414-6421.
[25]Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Ensl J Med,2005,353(2):123-132.
[26]刘建秋,吉峻嵘,蒋鹏娜.肺癌的中医病因病机研究进展[J].中华中医药学刊,2008：26(5)：912-913.
[27]刘嘉湘.实用中医肿瘤手册[M].上海：上海科技教育出版社,1996：109.
[28]赵炜.李佩文治疗肺癌的经验[J].北京中医,2002；21(6)：329—330.
[29]王银山.蔡光先教授论肺癌病因病机治则及用药特色[J].中医药学报.2003；21(1)：26-28.
[30]陈延武,樊惠连.胡国良老中医临证经验总结[J].湖南中医杂志,1998；14(3)：27-28.
[31]周岱翰.支气管肺癌的中医药治疗[J].新中医,1984；(1)：16—18.
[32]张霆.从络脉论治肺癌探讨[J].福建中医药.2007；38(1)：48-49.
[33]刘苓霜.刘嘉湘辨治肺癌经验[J].中医文献杂志,2006；(2)：38-40.
[34]李柳宁,陈海.刘伟胜教授治疗肺癌临证经验[J],中华中医药学学刊,2007；25(2)：217—218.
[35]谢刚.郭世雄主任医师治疗肺癌经验[J].四川中医,2006；24(3)：10—11.
[36]中华中医药学会.肿瘤中医诊疗指南[M],北京：中国中医药出版社,2008,第1版：10-12.
[37]李华.肺癌的中医辨治体会[J].光明中医2002；17(99)：20-21
[38]童康尔,尚官敏,葛丽娜.三蛇汤治疗晚期非小细胞肺癌44例[J].肿瘤学杂志.2008；14(12)：1014-1015.
[39]吴兰康,吴兰贞.吴氏抗癌散结膏及抗癌扶正散治疗中晚期肺癌62例观察[J].实用中医药杂志,1994；(3)：15-16.
[40]陈玉坤,吴玉生.除痰祛瘀法治肺癌的理论认识及临床应用[J].新中医.1993(1)：8-10.
[41]李佩文,贾立群,郝迎旭.养阴清肺方治疗肺癌的机制研究[J].北京中医药大学学报,2004；27(2)：64-67.
[42]刘显涛.肺抑瘤合剂治疗原发性支气管肺癌的临床研究[J].山东中医药大学学报,2004；28(2)：99-102
[43]刘晓光,杨海波,李璐,等.参一胶囊联合化疗治疗晚期非小细胞肺癌的疗效观察[J].吉林医学,2009；30(19)：2319-2320.
[44]耿传信,姚娟,王晓璐.平消胶囊联合化疗方案治疗晚期非小细胞肺癌46例[J].临床医药,2009；18(21)：68-69.
[45]李进章,姬发祥,赵久达.康艾注射液联合化疗治疗晚期非小细胞肺癌临床研究[J].中国现代医药杂志,2009；11(12)：12-13.
[46]杨宗艳,王莉娜.榄香烯注射液联合DP方案治疗老年晚期非小细胞肺癌疗效观察[J].湖南中医药大学学,2009；29(10)：5-7.
[47]朱宝江.黄芪注射液联合MVP方案治疗晚期非小细胞肺癌临床观察[J].中国医药指南,2010；8(2)：73-74.
[48]陈友云.康莱特注射液改善晚期肺癌患者恶液质症状(附42例)[J].现代肿瘤医学,2009；18(2)：306-307.
[49]刘培民,张翼,宋娟.十二味抑瘤胶囊联合GP方案化疗治疗中晚期非小细胞肺癌30例[J].中医研究,2009；22(10)：20-21.
[50]张学民,周永明,钱钢,等.中药配合化疗治疗中晚期非小细胞肺癌的临床研究[J].辽宁中医药大学学报,2008；10(5)：77-78.
[51]黎壮伟,陈锐深,张广丽.仙鱼汤配合化疗治疗中晚期非小细胞肺癌疗效观察[J].辽宁中医杂志,2008：35(4)：550-551.
[52]王炳胜,彭东长,李德炳.益气活血养阴方配合放疗治疗肺癌131例[J].中国中西医结合杂志,2006；26.(10)：942-943.
[53]陈凡,王晓莉.康艾注射液对Ⅲ,Ⅳ期非小细胞肺癌放疗增效减毒作用的临床观察[J].中国中药杂志,2006：31(18)：1553-1554.
[54]寿伟臻,刘嘉湘,沈德义.中药参麦制剂对肺癌患者介入治疗中免疫功能的影响[J].辽宁中医杂志,2006；33(2)：175-176.
[55]刘城林,王远东,金学军.中药配合支气管动脉灌注化疗治疗非小细胞肺癌的临床观察[J].中国中西医结合杂志,2001；21(8)：579-581.
[56]郑香玲,陈明跃,田燕晓.癌枯肺癌瘤体内注入实验与临床应用的初步研究[J]肿瘤防治杂志,2001；8(3)：266—268.
[57]张沁园.中药结合ET—SPACETM-I全身热疗治疗54例肺癌临床疗效观察[J].实用中西医结合临床,2006；6(5)：1-2.
[58]陈立伟,汪瑜菡.热疗联合中医辨证用药对改善恶性肿瘤患者免疫力及生活质量的研究[J].四川中医,2006；24(2)：63-64.
[59]邓俭.华蟾素联合吉非替尼治疗晚期非小细胞肺癌临床观察[J].中国现代药物应用,2007；1(11)：29—30.
[60]曹洋,谭开基,陈志坚.中医药配合易瑞沙治疗肺癌2例[J].新中医,2008；40(3)：104-105.
[61]周岱翰,林丽珠,陶志广.中医肿瘤疗效评价系统在晚期非小细胞肺癌中的应用 [J].中国肿瘤,2005,14(10)：654.
[62]阙华发,陈红风,徐杰男.生命质量与中医药治疗恶性肿瘤临床疗效评价标准探讨[J].中西医结合学报,2005,3(4)：253—256.
[63]张健.生活质量研究与恶性肿瘤的中医疗效评价[J].北京中医药大学学报,2000；23(2)：67—69.
[64]张培彤.中医肿瘤临床疗效标准的探讨[J].中国肿瘤,1999；8(10)：452-454.
[65]李忠,陈信义,刘丹.肺癌中医“杂合以治”临床治疗思路[J].中国中医基础医学杂志,2005；11(2)：149～150.
[66]薛暖珠,林丽珠.中医肿瘤疗效评价标准在晚期非小细胞肺癌的应用[J].广州中医药大学学报,2009：26(2)：108-112.
[67]刘嘉湘.扶正法治疗122例晚期原发性肺癌的前瞻性研究[J]。中国医药学报,1987；(1)：11.
[68]BingKui.Piao.The Clinical Observation for the Treatment of Lung Cancer Ointment to advance stage Constitutional Lung Cancer--to attach 399 example for the Clinical Analysis [J]. Journal of China Prescription Drug 1991.04.
[69]李佩文.平肺方治疗非小细胞肺癌109例临床观察[J].中医杂志,1995；.36(2)：87-88.
[70]李金瀚.中医药与化疗结合治疗肺癌临床观察[J].中国中西医结合杂志,1996；16(3)：136-138.
[71]刘燕珠.中西医结合治疗晚期肺癌36例临床观察[J].福建中医药,1997；28(5)：4-5.
[72]陈志峰.中医药治疗原发性非小细胞肺癌疗效meta分析[J].中医杂志,1999；40(5)：287-289.
[73]刘颖莉.晚期非小细胞肺癌的中医药治疗疗效观察[J].辽宁中医杂志,2005；32(10)：1023.
[74]李柳宁,刘伟胜.中医辨证施治结合化疗对中晚期非小细胞肺癌预后因子的影响.中国中西医结合杂志,2003；1(23)：8.
[75]孙钢,刘嘉湘.辨治肺癌的特色[J].中医杂志,2000；41(2)：75.
[76]周岱翰.支气管肺癌的中医药治疗[J].新中医,1984；(1)：16—18.
[77]郁仁存.中医肿瘤学(上册).北京：科学出版社,1997；274-28.
[78]施志明.原发性肺癌中医辨证分型与西医分期及细胞类型关系[J].中国癌症杂志,1998；8(4)：317.
[79]吴燕波,蔡明明,朱旭东.100例原发性肺癌中医辨证分型与临床病理分型的关系[J].江苏中医,1993；(2)：11.
[80]陈锐深,曹洋.辨证论治肺癌132例分析[J].中医药学刊,2005；23(4)：593.
[81]侯丽,姜苗,陈信义,等.晚期非小细胞肺癌中医证候特征回顾性临床研究[J].中国中医药信息杂志,2007；4(4)：19-21.
[82]左明焕,王芬,孙韬.晚期肺癌的中医证候研究[J].北京中医药大学学报,2003；12(10)：7.
[83]胡小梅,张培彤,扬宗艳.中晚期非小细胞肺癌患者中医证型分布规律研究[J].中国肿瘤,2007；1(16)：51-53.
[84]左明焕,胡凯文,陈信义.非小细胞肺癌患者手术前后中医证候特征研究[J].中医杂志,2002；8(43)：615-617.
[85]黎敬波,张征,林丽珠.非小细胞肺癌手术前后证候变化的对照研究[J].新中医,2008；40(9)：24-26.
[86]孙韬,胡凯文,姜敏.非小细胞肺癌氩氦刀冷冻治疗前后中医证候特点研究.北京中医药大学学报(中医临床版),2007；1(14)：22-24.
[87]尤建良.培土生金法在肺癌治疗中的运用,河南中医,2006；(33)12：1568-1569.
[88]戴林.康肺汤在肺癌治疗中的运用,吉林中医药2002； (22)6：15.
[89]梁凤凌,周德瑞,段国勋,等.培土生金法治疗肺癌21例疗效观察.山西中医,1996；(12)6：9-10.
[90]罗海英,徐凯,刘伟胜.仙龙定痛饮治疗骨转移癌痛32例[J].河北中医,2004：26(3)：174-175.
[91]郑筱萸.人民共和国卫生部.中药新药临床研究指导原则：第1辑[S].2002：64—68.
[92]国家技术监督局.GB／T16751.2—1997中医临床诊疗术语证候部分[S]北京：中国标准出版社,1997.
[93]查人俊.现代肺ca诊断与治疗.北京：人民军医出版社,1993：92-97、292.
[2]Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Ensl J Med,2002; 346(2): 92-98.
[3]Kubota K,Watanabe K,Kunitoh H,et al.Phase Ⅲ randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stag e Ⅳ non-small-cell lung cancer:the Japanese Taxotere Lung Cancer Study Group [J]. J Clin Oncol,2004; 22 (2):254-261.
[4]ParkinDM, BrayFB, PisaniP. Global cancer statistics[J]. CA Cancer J Clin, 2005,55(2):74—108.
[5]支修益.我国肺癌流行病学的研究[J]中国处方药,2009；2(83)：56—57。
[6]Jovanovic D, Popevic S, StevicR, etal. Changes in lung cancer presentation in 13year interval (comparison of data bases from 1990 and 2003)[J]. Lung Cancer,2005,49(Suppl2):191.
[7]YangP, WilliamsB, AdjeiA, etal. Characteristics of lung cancer patients who were diagnosed younger than 50 or older than 80 years of age. LungCancer, 2005,49(Suppl2):S22-58.
[8]王瑾,许峰,周清华.肺癌流行病学研究进展[J]中国肺癌杂志,2005：8(5)：395—398.
[9]AllenJ, JahanzebM. Neoadjuvant chemotherapy in stage III NSCLC[J].J Natl Compr Cane Netw,2008; 6(3):285-293.
[10]谷力加,吴一龙,冯卫能.237例肺癌外科治疗影响预后因素的分析[J].中国肿瘤临床,2002；29(6)：410-412.
[11]Baumann M A pold S, Petemon C, et al. Dose and fraction—ation concepts in the primary radiotherapy of non—small cell lung cancer [J]. Lung Cancer.2001,33:S43—S45
[12]徐建宇.非小细胞肺癌非常规分割三维适形放射治疗的研究现状.实用肿瘤内科学.2008：22(5)：34-35.
[13]OnishiH, ArakiT, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma:clinical outcomes in 245 Subjects in a Japanese multi institutional study. Cancer 2004; 101 (7):1623-1631.
[14]0nishiH, ShiratoH, NagataY, et al.Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ non-small cell lung cancer:updated results of 257 patients in a Japanese multi-institutional study[J]. Thorac Oncol 2007;2(7Suppl 3):S94-100.
[15]Chemotherapy in non small cell lung cancer a meta-analysis using updated data on individual patients from 52 randomised clinical trials[J]. BMJ, 1995; 311:899—909.
[16]Pignon JP, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Grou[J]p. Clin Oncol 2008;26(21):3552-3559.
[17]Scagliotti GV, De Marlnis F, Rinaldi M, et al. Phase Ⅰ11 Randomized trial comparing three platinum-based doublets in advanced non—small cell lung cancer [J]. Clin Oncol,2002,20(21):4285—4291.
[18]Hainsworth JD, Gray JR, Morrlssey LH, et al. Long—term follow—up of patients treated with pa elitaxel/earbo platin—based chemotherapy for advanced non-small-cell lung cancer:sequential phase Ⅱ trials of the minnie pearl cancer research network [J]. ClinOncol,2002,20(13):2937-2942.
[19]Laack E, Mende T, Drk H, et al. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer:a phase Ⅱ trial[J]. Eur J Cancer,2002,38(5):654-660.
[20]Fossella FV, DeVoreKerr RN, etal. Randomized phase Ⅲ trial of ocetaxel versus vinorel bineo rifosf amidein patient swith advanced on-small—cell lung cancer previous lytreated with platinum—containing chemotherapy regime. TheTAX320 Non—Small Cell Lung Cancer Study Group. JClinOncol,2000, 18(12):2354--2362.
[21]Fossella. FV, LynchT'Shepherd.FA. Second-line chemotherapy For NSCLC: establishing a gold standard[J]. Lung Cancer.2002; 38 (14):5—12.
[22]Demarinis F, PaulS, Hanna N, etal. Survival update for the phaseⅢstudy of pemetre xedvsdocetaxel in non-small cell lung cancer(NSCLC) [J]. ASCO Meeting Abstracts, Jun2006; 24:7133.
[23]熊慧华,邹艳梅,夏署.吉非替尼与多西紫杉醇二线治疗非小细胞肺癌的疗效比较[J].临床内科杂志,2008；25(8)：537-538.
[24]Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small--cell lung cancer after failure of at least one prior chemotherapy regimen[J]. Clin Cancer Res,2005,11(18):6414-6421.
[25]Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Ensl J Med,2005,353(2):123-132.
[26]刘建秋,吉峻嵘,蒋鹏娜.肺癌的中医病因病机研究进展[J].中华中医药学刊,2008：26(5)：912-913.
[27]刘嘉湘.实用中医肿瘤手册[M].上海：上海科技教育出版社,1996：109.
[28]赵炜.李佩文治疗肺癌的经验[J].北京中医,2002；21(6)：329—330.
[29]王银山.蔡光先教授论肺癌病因病机治则及用药特色[J].中医药学报.2003；21(1)：26-28.
[30]陈延武,樊惠连.胡国良老中医临证经验总结[J].湖南中医杂志,1998；14(3)：27-28.
[31]周岱翰.支气管肺癌的中医药治疗[J].新中医,1984；(1)：16—18.
[32]张霆.从络脉论治肺癌探讨[J].福建中医药.2007；38(1)：48-49.
[33]刘苓霜.刘嘉湘辨治肺癌经验[J].中医文献杂志,2006；(2)：38-40.
[34]李柳宁,陈海.刘伟胜教授治疗肺癌临证经验[J],中华中医药学学刊,2007；25(2)：217—218.
[35]谢刚.郭世雄主任医师治疗肺癌经验[J].四川中医,2006；24(3)：10—11.
[36]中华中医药学会.肿瘤中医诊疗指南[M],北京：中国中医药出版社,2008,第1版：10-12.
[37]李华.肺癌的中医辨治体会[J].光明中医2002；17(99)：20-21
[38]童康尔,尚官敏,葛丽娜.三蛇汤治疗晚期非小细胞肺癌44例[J].肿瘤学杂志.2008；14(12)：1014-1015.
[39]吴兰康,吴兰贞.吴氏抗癌散结膏及抗癌扶正散治疗中晚期肺癌62例观察[J].实用中医药杂志,1994；(3)：15-16.
[40]陈玉坤,吴玉生.除痰祛瘀法治肺癌的理论认识及临床应用[J].新中医.1993(1)：8-10.
[41]李佩文,贾立群,郝迎旭.养阴清肺方治疗肺癌的机制研究[J].北京中医药大学学报,2004；27(2)：64-67.
[42]刘显涛.肺抑瘤合剂治疗原发性支气管肺癌的临床研究[J].山东中医药大学学报,2004；28(2)：99-102
[43]刘晓光,杨海波,李璐,等.参一胶囊联合化疗治疗晚期非小细胞肺癌的疗效观察[J].吉林医学,2009；30(19)：2319-2320.
[44]耿传信,姚娟,王晓璐.平消胶囊联合化疗方案治疗晚期非小细胞肺癌46例[J].临床医药,2009；18(21)：68-69.
[45]李进章,姬发祥,赵久达.康艾注射液联合化疗治疗晚期非小细胞肺癌临床研究[J].中国现代医药杂志,2009；11(12)：12-13.
[46]杨宗艳,王莉娜.榄香烯注射液联合DP方案治疗老年晚期非小细胞肺癌疗效观察[J].湖南中医药大学学,2009；29(10)：5-7.
[47]朱宝江.黄芪注射液联合MVP方案治疗晚期非小细胞肺癌临床观察[J].中国医药指南,2010；8(2)：73-74.
[48]陈友云.康莱特注射液改善晚期肺癌患者恶液质症状(附42例)[J].现代肿瘤医学,2009；18(2)：306-307.
[49]刘培民,张翼,宋娟.十二味抑瘤胶囊联合GP方案化疗治疗中晚期非小细胞肺癌30例[J].中医研究,2009；22(10)：20-21.
[50]张学民,周永明,钱钢,等.中药配合化疗治疗中晚期非小细胞肺癌的临床研究[J].辽宁中医药大学学报,2008；10(5)：77-78.
[51]黎壮伟,陈锐深,张广丽.仙鱼汤配合化疗治疗中晚期非小细胞肺癌疗效观察[J].辽宁中医杂志,2008：35(4)：550-551.
[52]王炳胜,彭东长,李德炳.益气活血养阴方配合放疗治疗肺癌131例[J].中国中西医结合杂志,2006；26.(10)：942-943.
[53]陈凡,王晓莉.康艾注射液对Ⅲ,Ⅳ期非小细胞肺癌放疗增效减毒作用的临床观察[J].中国中药杂志,2006：31(18)：1553-1554.
[54]寿伟臻,刘嘉湘,沈德义.中药参麦制剂对肺癌患者介入治疗中免疫功能的影响[J].辽宁中医杂志,2006；33(2)：175-176.
[55]刘城林,王远东,金学军.中药配合支气管动脉灌注化疗治疗非小细胞肺癌的临床观察[J].中国中西医结合杂志,2001；21(8)：579-581.
[56]郑香玲,陈明跃,田燕晓.癌枯肺癌瘤体内注入实验与临床应用的初步研究[J]肿瘤防治杂志,2001；8(3)：266—268.
[57]张沁园.中药结合ET—SPACETM-I全身热疗治疗54例肺癌临床疗效观察[J].实用中西医结合临床,2006；6(5)：1-2.
[58]陈立伟,汪瑜菡.热疗联合中医辨证用药对改善恶性肿瘤患者免疫力及生活质量的研究[J].四川中医,2006；24(2)：63-64.
[59]邓俭.华蟾素联合吉非替尼治疗晚期非小细胞肺癌临床观察[J].中国现代药物应用,2007；1(11)：29—30.
[60]曹洋,谭开基,陈志坚.中医药配合易瑞沙治疗肺癌2例[J].新中医,2008；40(3)：104-105.
[61]周岱翰,林丽珠,陶志广.中医肿瘤疗效评价系统在晚期非小细胞肺癌中的应用 [J].中国肿瘤,2005,14(10)：654.
[62]阙华发,陈红风,徐杰男.生命质量与中医药治疗恶性肿瘤临床疗效评价标准探讨[J].中西医结合学报,2005,3(4)：253—256.
[63]张健.生活质量研究与恶性肿瘤的中医疗效评价[J].北京中医药大学学报,2000；23(2)：67—69.
[64]张培彤.中医肿瘤临床疗效标准的探讨[J].中国肿瘤,1999；8(10)：452-454.
[65]李忠,陈信义,刘丹.肺癌中医“杂合以治”临床治疗思路[J].中国中医基础医学杂志,2005；11(2)：149～150.
[66]薛暖珠,林丽珠.中医肿瘤疗效评价标准在晚期非小细胞肺癌的应用[J].广州中医药大学学报,2009：26(2)：108-112.
[67]刘嘉湘.扶正法治疗122例晚期原发性肺癌的前瞻性研究[J]。中国医药学报,1987；(1)：11.
[68]BingKui.Piao.The Clinical Observation for the Treatment of Lung Cancer Ointment to advance stage Constitutional Lung Cancer--to attach 399 example for the Clinical Analysis [J]. Journal of China Prescription Drug 1991.04.
[69]李佩文.平肺方治疗非小细胞肺癌109例临床观察[J].中医杂志,1995；.36(2)：87-88.
[70]李金瀚.中医药与化疗结合治疗肺癌临床观察[J].中国中西医结合杂志,1996；16(3)：136-138.
[71]刘燕珠.中西医结合治疗晚期肺癌36例临床观察[J].福建中医药,1997；28(5)：4-5.
[72]陈志峰.中医药治疗原发性非小细胞肺癌疗效meta分析[J].中医杂志,1999；40(5)：287-289.
[73]刘颖莉.晚期非小细胞肺癌的中医药治疗疗效观察[J].辽宁中医杂志,2005；32(10)：1023.
[74]李柳宁,刘伟胜.中医辨证施治结合化疗对中晚期非小细胞肺癌预后因子的影响.中国中西医结合杂志,2003；1(23)：8.
[75]孙钢,刘嘉湘.辨治肺癌的特色[J].中医杂志,2000；41(2)：75.
[76]周岱翰.支气管肺癌的中医药治疗[J].新中医,1984；(1)：16—18.
[77]郁仁存.中医肿瘤学(上册).北京：科学出版社,1997；274-28.
[78]施志明.原发性肺癌中医辨证分型与西医分期及细胞类型关系[J].中国癌症杂志,1998；8(4)：317.
[79]吴燕波,蔡明明,朱旭东.100例原发性肺癌中医辨证分型与临床病理分型的关系[J].江苏中医,1993；(2)：11.
[80]陈锐深,曹洋.辨证论治肺癌132例分析[J].中医药学刊,2005；23(4)：593.
[81]侯丽,姜苗,陈信义,等.晚期非小细胞肺癌中医证候特征回顾性临床研究[J].中国中医药信息杂志,2007；4(4)：19-21.
[82]左明焕,王芬,孙韬.晚期肺癌的中医证候研究[J].北京中医药大学学报,2003；12(10)：7.
[83]胡小梅,张培彤,扬宗艳.中晚期非小细胞肺癌患者中医证型分布规律研究[J].中国肿瘤,2007；1(16)：51-53.
[84]左明焕,胡凯文,陈信义.非小细胞肺癌患者手术前后中医证候特征研究[J].中医杂志,2002；8(43)：615-617.
[85]黎敬波,张征,林丽珠.非小细胞肺癌手术前后证候变化的对照研究[J].新中医,2008；40(9)：24-26.
[86]孙韬,胡凯文,姜敏.非小细胞肺癌氩氦刀冷冻治疗前后中医证候特点研究.北京中医药大学学报(中医临床版),2007；1(14)：22-24.
[87]尤建良.培土生金法在肺癌治疗中的运用,河南中医,2006；(33)12：1568-1569.
[88]戴林.康肺汤在肺癌治疗中的运用,吉林中医药2002； (22)6：15.
[89]梁凤凌,周德瑞,段国勋,等.培土生金法治疗肺癌21例疗效观察.山西中医,1996；(12)6：9-10.
[90]罗海英,徐凯,刘伟胜.仙龙定痛饮治疗骨转移癌痛32例[J].河北中医,2004：26(3)：174-175.
[91]郑筱萸.人民共和国卫生部.中药新药临床研究指导原则：第1辑[S].2002：64—68.
[92]国家技术监督局.GB／T16751.2—1997中医临床诊疗术语证候部分[S]北京：中国标准出版社,1997.
[93]查人俊.现代肺ca诊断与治疗.北京：人民军医出版社,1993：92-97、292.